News

Pre-existing dry eye can affect the outcomes of excimer laser refractive and cause significant postoperative morbidity as well as patient dissatisfaction. Therefore, preoperative screening for dry eye is critical, said Michael B. Raizman, MD.

The availability of a new cataract surgery platform from Abbott Medical Optics (AMO) marks the second phacoemulsification system launched by the company in the United States this year.

Working in an ambulatory surgery center can be a good choice for ophthalmologists, particularly cataract surgeons, because they let them use their time efficiently while delivering excellent care without the hassles of working in a larger hospital setting where ophthalmology may not be a priority.

Best-corrected visual acuity does not capture the degree of impairment in some patients, such as those with geographic atrophy, particularly as they try to read across a page. A new patient-reported outcome measure has been found to correlate well with a more objective measurement of performance.

In this Q&A, Ophthalmology Times talks to Michael Repka, MD, MBA and medical director of government affairs for the American Academy of Ophthalmology how the transition to ICD-10 is affecting ophthalmologists.

A new wearable adaptive refractor (VisionFit; Adaptica, Padova, Italy) for subjective refraction combines the features of trial frames and manual and automated phoropters. With this mobile device, patients can be examined while sitting or standing, and the unit itself can be easily transported.

An anterior segment diagnostic imaging platform based on high-speed swept-source OCT is being developed by Heidelberg Engineering. It will provide biometry as well as corneal topography and tomography, while also enabling visualization of the anterior and posterior lens surfaces and assessment of the anterior chamber angle.

Robert Dempsey, vice president and business unit head at Shire Pharmaceutical’s Ophthalmics Business Unit, recently talked with Ophthalmology Times Group Content Director Mark L. Dlugoss about Shire’s entry into the eye care market. Among the topics discussed are Shire’s attraction to the market, Lifitegrast–its potential dry eye drug, and other potential ophthalmic compounds.